Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of 684 shares represented by Restricted Stock Units dated 05/18/2026. The filing also lists multiple 10b5-1 sales by Daan Guido Maria Van Well totaling several transactions in March–April 2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice documenting planned and recent dispositions of Common Stock linked to Restricted Stock Units. The filing lists an intended sale of 4,608 shares of Common Stock from Restricted Stock Units dated 05/18/2026. It also itemizes multiple 10b5-1 sales by the holder between 03/13/2026 and 05/13/2026, including transactions of 4,000 and 4,414 shares on individual dates. The cover data shows 68,486,338 shares referenced alongside the filing date 05/19/2026.
SOPHiA GENETICS SA filed a Form 6-K noting that it has published its 2025 Environmental, Social and Governance (ESG) Impact Summary as of December 31, 2025. The summary is made available on the company’s website in the Investor Relations section.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.5421 per share. The sale was executed under a pre-established Rule 10b5-1(c) trading plan, and Xu held 626,888 shares directly after the transaction.
SOPHiA GENETICS SA director Kathy L. Hibbs reported an open-market sale of 7,508 Ordinary Shares on May 12, 2026. The shares were sold at a weighted average price of $4.6666 per share, in multiple trades between $4.54 and $4.85.
The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Hibbs directly owns 89,768 Ordinary Shares. This represents a partial reduction of her holdings while retaining a substantial remaining position in the company.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on May 12, 2026 at a weighted average price of $4.6689 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan, and Menu now holds 256,388 shares directly.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 ordinary shares in an open-market transaction. The sale took place at a weighted average price of $5.0872 per share under a duly adopted Rule 10b5-1(c) trading plan. Following this transaction, he reports direct ownership of 3,633,981 ordinary shares.
SOPHiA GENETICS SA has called its 2026 Annual General Meeting for June 18, 2026 in Rolle, Switzerland, asking shareholders to approve 2025 financial statements, compensation budgets and an increase in conditional share capital. The Board also proposes amending the articles to allow up to 24,807,564 conditional shares for employee participation.
In 2025, the company generated IFRS revenue of $77.3 million, up 19% year over year, but recorded an IFRS net loss of $79.0 million and adjusted EBITDA of –$41.5 million. Adjusted gross margin was 74.2%, and the accumulated deficit to be carried forward totals CHF 403.8 million.
The letter highlights 391,000 platform analyses in 2025 (over 2.3 million since inception), 993 customers and net dollar retention rising to 115% with churn below 1%. Founder Dr. Jurgi Camblong plans to transition to Executive Chair (subject to election), while President Ross Muken becomes CEO effective July 1, 2026.
SOPHiA GENETICS reported higher Q1 2026 revenue but remained loss-making. Revenue reached $21.7 million, up 22% year over year, driven mainly by SOPHiA DDM Platform usage. Gross margin stayed strong at 68%. The company posted a net loss of $19.3 million, or $(0.27) per share.
Cash and cash equivalents were $65.4 million with borrowings of $47.8 million. SOPHiA raised $14.5 million via an at-the-market share program. Platform analysis volume grew 16% to 107,576, Core Genomics Customers increased to 537, and net dollar retention reached 117%, reflecting greater spending by existing customers.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu executed an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.8178 per share. Following this transaction, he directly holds 261,388 Ordinary Shares. The sale was made under a duly adopted Rule 10b5-1(c) trading plan.